RecruitingPhase 2NCT05389293
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Lorenzo Falchi, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Mosunetuzumab(drug)
- Enrollment
- 152 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (9)
- Georgetown University (Data Collection Only), Washington D.C., District of Columbia, United States
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, New Jersey, United States
- Hackensack Meridian Health (Data collection only), Hackensack, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk- Commack (Limited protocol activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05389293 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca